CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
Lumacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR
Lung Function Decline is Delayed But Not Decreased in Patients With Cystic Fibrosis and the R117H Gene Mutation
Evaluation of a systems biology approach to identify pharmacological correctors of the mutant CFTR chloride channel
Bronchial epithelial cell lines and primary nasal epithelial cells from cystic fibrosis respond differently to cigarette smoke exposure
